Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies

  • Bash E
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.

Author-supplied keywords

  • icle

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Eleanor Bash

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free